Nstemi treatment guideline
[DOCX File]www.auctoresonline.org
https://info.5y1.org/nstemi-treatment-guideline_1_7de9bc.html
According to 2020 ESC guideline on selection of NSTEMI treatment strategy based on risk stratification, she classified as very high risk patient, CAG recommendation was class I and level C. So she received CAG, the result showed coronary atherosclerosis with slight stenosis. Therefore she transferred to cardiology department, with blood pressure 115/70 mmHg, pulse 113 times/min, breath rate 31 ...
[DOC File]Content Model
https://info.5y1.org/nstemi-treatment-guideline_1_28a57d.html
Treatment Most cases of STEMI are treated with thrombolysis or if possible with percutaneous coronary intervention (PCI, angioplasty and stent insertion), provided the hospital has facilities for coronary angiography. NSTEMI is managed with medication, although PCI …
[DOC File]Part 5: Acute Coronary Syndromes
https://info.5y1.org/nstemi-treatment-guideline_1_452911.html
Treatment Recommendation. High-risk UA/NSTEMI. If revascularization therapy (PCI or surgery) is planned, it is safe to give GP IIb/IIIa inhibitors in addition to standard therapy (including ASA and heparin) to patients with high-risk UA/NSTEMI in the ED. This therapy may reduce the risk of death or recurrent ischemia. High-risk features of UA/NSTEMI are defined in the consensus on science ...
[DOC File]NSTEMI INITIAL DOSING GUIDE
https://info.5y1.org/nstemi-treatment-guideline_1_8e7c6e.html
NSTEMI INITIAL DOSING GUIDE (Referenced Version) This . dosing guide. lists initial drugs and doses that should be highly considered based upon recent clinical practice guidelines, medication package inserts, and emerging evidence. WEIGHT AND CREATININE CLEARANCE. Determine patient’s weight (kg) Determine CrCl ml/min = (140 – age) X weight (kg)/(serum creatinine X 72) multiply by 0.85 if ...
[DOC File]www.pbm.va.gov
https://info.5y1.org/nstemi-treatment-guideline_1_125e04.html
Goals of treatment of UA/NSTEMI are to provide immediate relief of ischemia and prevent serious outcomes including death or MI. In STEMI, the immediate goal is to restore perfusion. Platelet adhesion, activation, and aggregation are stimulated in ACS, and anti-platelet therapy is a key component of therapy.
[DOC File]STEMI standing orders
https://info.5y1.org/nstemi-treatment-guideline_1_596be6.html
b Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology …
[DOC File]Manitoba ACS Network
https://info.5y1.org/nstemi-treatment-guideline_1_6dc4de.html
In the Province of Manitoba, ACS including unstable angina, non-ST-segment elevation MI (NSTEMI), and ST segment elevation MI (STEMI) is a major reason for hospitalization and death. Data for Manitoba from the Canadian Institute for Health Information (CIHI) indicates that in 2011 age-standardized rate/100,000 for NSTEMI and STEMI is 230 with 6.6% 30 day mortality and a readmission rate of 9% ...
National Institute for Clinical Excellence
2 3.1 119 Lines 14-16 In line with previous footnotes regarding the licensed indications for other therapy classes (e.g. GPIs), a footnote should be added to state that the LMWHs with licensed indications for the treatment of UA and NSTEMI are enoxaparin and dalteparin. Thank you but this is already discussed in the introduction to the chapter. Sanofi-aventis 3 3.2.6 137 Line 19 the incorrect ...
[DOC File]NSTEMI standing orders
https://info.5y1.org/nstemi-treatment-guideline_1_81f063.html
For UA/NSTEMI patients in whom an initial invasive strategy is selected, it is reasonable to initiate antiplatelet therapy with both clopidogrel (loading dose followed by daily maintenance dose) and a GP IIb/IIIa inhibitor (Class IIa, LOE: B).
[DOC File]National PBM Monograph Template
https://info.5y1.org/nstemi-treatment-guideline_1_4eaeaa.html
In the treatment of UA/NSTEMI, enoxaparin (Level of Evidence A), UFH (Level of Evidence A), and fondaparinux (Level of Evidence B) are acceptable Class I recommended anticoagulants for invasive or conservative strategies. Fondaparinux or enoxaparin should be continued until discharge, up to 8 days. Fondaparinux may be a preferable agent in patients in whom a conservative strategy is planned ...
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.